October 2016

New Product - Actair

Actair (European house dust mite (Dermatophagoides pteronyssinus) and American house dust mite (Dermatophagoides farinae)) treatment has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation. IR (Index of Reactivity): The IR unit has been defined to measure the allergenicity of an allergen extract. The IR unit of Stallergenes is not comparable to the units used by other allergen manufacturers. Actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults and adolescents over 12 years diagnosed with house dust mite allergy. Actair is contraindicated in severe, uncontrolled or unstable asthma; immune deficiency diseases or active forms of auto‑immune disorder; malignant diseases (e.g. cancer) and in oral inflammations (such as oral lichen planus, oral ulcerations or oral mycosis). Actair is available as a 50% mixture of house dust mite allergen extracts of D. pteronyssinus and D. farinae: 1) initiation treatment pack of 1 containing 3 sublingual tablets of 100 IR plus 28 sublingual tablets of 300 IR in a blister; 2) continuation treatment pack of 1 containing 30 sublingual tablets of 300 IR in a blister.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629